Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites?
Basu
Sandip
S
Alavi
Abass
A
D002277:Carcinoma / Q000000981:diagnostic imaging* / Q000473:pathology; D002986:Clinical Trials as Topic / Q000592:standards*; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D019788:Fluorodeoxyglucose F18; D017408:Guidelines as Topic; D006801:Humans; D049268:Positron-Emission Tomography / Q000592:standards*; D011785:Quality Assurance, Health Care / Q000379:methods / Q000592:standards*; D011859:Radiography; D019275:Radiopharmaceuticals
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18